With further research, it is expected to transform from a research tool into a clinical drug, filling the niche in targeted metabolic therapy, especially in the combined intervention of obesity and type 2 diabetes, where it holds unique application potential
At the end of 16 weeks, the animals were fasted overnight and then euthanized by exposure to isoflurane (Webster Veterinary Supply Inc., Devens, MA)

Body Composition and Metabolic Parameters Research on component peptides revealed favorable effects on body composition and metabolic markers[10]: Significant reductions in waist circumference (10-15 cm reductions observed) Preferential visceral fat loss documented through imaging studies Preserved lean body mass relative to total weight loss in most studies Improved body composition ratios with fat mass reductions exceeding total weight loss percentages Type 2 Diabetes Research Glycemic Control Studies Investigations in type 2 diabetes models demonstrated robust glucose-lowering effects[11]: HbA1c reductions of 2.0-2.4% observed with GLP3 in phase 2 diabetes trials Fasting plasma glucose reductions of 40-60 mg/dL documented across dose ranges Improved continuous glucose monitoring parameters including time in range and glucose variability CagriSema combination achieved superior glycemic control compared to individual components Studies showed that 72% of participants with prediabetes reverted to normoglycemia with GLP3 treatment, suggesting potential diabetes prevention applications[12]

[5], [6] The actual goal of gerontocosmetology is to find new effective and harmless low-molecular substances as the short tetrapeptide Epithalon could also be like
This comprehensive, multi-pathway approach is why many functional medicine practitioners consider this synergy a foundational element for patients learning how to live with long-term COVID